Search

A 76-year-old woman developed sprue-like enteropathy while being treated with olmesartan-medoxomil for hypertension. Initially misdiagnosed with post-infectious irritable bowel syndrome or viral gastroenteritis, she experienced worsening symptoms and was eventually diagnosed with olmesartan-medoxomil induced sprue-like enteropathy. Treatment with budesonide led to an improvement in her condition within a week. [Extracted from the article]

A 38-year-old woman with relapsing remitting multiple sclerosis (RRMS) experienced various toxicities during treatment with ocrelizumab, interferon-beta-1a, and fingolimod. She developed acute enteritis, colitis, and infusion-related reactions while on ocrelizumab, and exhibited lack of efficacy with interferon-beta-1a and fingolimod. Despite experiencing gastrointestinal symptoms and colitis, she remained stable neurologically after discontinuing ocrelizumab and starting ofatumumab in January 2024. [Extracted from the article]

A female patient with developmental epileptic encephalopathies and severe behavioral problems, sleep disturbances, insomnia, intellectual disability, and refractory seizures was treated with multiple antiepileptic drugs (clobazam, lamotrigine, topiramate, valproic acid, and lacosamide) but did not achieve seizure-freedom. At the age of 30, she received off-label treatment with cannabidiol, which resulted in a reduction in seizure frequency and improvement in her symptoms. This case suggests that cannabidiol may be effective in treating developmental epileptic encephalopathies. [Extracted from the article]

A 9-month-old boy with Kawasaki disease (KD) exhibited lack of efficacy during treatment with immune-globulin. Initially diagnosed with acute viral gastroenteritis, the boy developed rapidly increasing neck swelling and periorbital edema. After a clinical diagnosis of KD was made, he received two doses of immune-globulin but remained febrile. Pulse systemic corticosteroid therapy was initiated, and the boy eventually improved and was discharged in stable condition. Aspirin was continued for 6 months post-discharge. [Extracted from the article]

Hypernatreamia secondary to salt intoxication following erroneous administration hypertonic sodium chloride was considered. It was discovered that he received hypertonic IV sodium chloride 1 mmoL/mL (200mL) infusion instead of isotonic sodium chloride by error. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 3-week-old boy developed hypernatraemia secondary to salt intoxication during treatment with sodium chloride for viral gastroenteritis and hyperglycaemia during treatment with glucose for hypernatraemia following medication error and exhibited lack of efficacy with midazolam and thiopental sodium treatment for seizures [ I not all routes, dosages and outcomes stated; duration of treatments to reactions onsets not stated i ]. [Extracted from the article]

However, the treatment with prednisone was unsuccessful (lack of response). Non-lupus full-house nephropathy-immune dysregulation as a rare cause of pediatric nephrotic syndrome: Questions. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 6-year-old boy exhibited lack of response to prednisone during treatment for nephrotic syndrome (NS). [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event An 18-month-old girl exhibited lack of efficacy with ondansetron, while being treated for vomiting [1]. She was started on unspecified IV fluids and ondansetron [ I route and dosage not stated i ]; however no improvement in symptoms was observed over the course of two days (lack of efficacy) and oral challenges continued to fail. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event * Drug overdose A 6-month-old boy developed bradycardia, reduced responsiveness, hypotension, poor perfusion, wide QRS complex, atrioventricular dissociation, ventricular escape rhythm and right bundle branch block secondary to flecainide toxicity due to flecainide overdose [ I dosage, duration of treatment to reactions onsets and outcomes not stated i ]. Clinical examination revealed hypotension, bradycardia and poor perfusion. [Extracted from the article]

In a retrospective review of 1260 paediatric patients treated for infantile haemangiomas between August 2013 and January 2016, 26 infants [19 girls and 7 boys; I exact ages not clearly stated i ] were identified, who developed sleep disturbance (17 patients), agitation (3 patients), hypoglycaemia (2 patients), bronchial hyperreactivity (2 patients) or bronchospasm (2 patients) during treatment with propranolol. However, after 4-240 days of propranolol initiation, the patients developed side effects, including sleep disturbance (17 patients), agitation (3 patients), grade 3 hypoglycaemia (2 patients), grade 4 bronchial hyperreactivity (2 patients) or bronchospasm (2 patients). B Author comment: b I "Of the 1260 patients, 26 patients (2.1%) experienced [intolerable side effects] that were identified by the investigators as being at least possibly treatment-related." i. [Extracted from the article]

In a retrospective cohort study of 124 neonates, admitted to the neonatal ICU between October 2010 and September 2015, two neonates [ I exact ages not stated; sexes not stated i ] were described, who developed cholestasis during treatment with parenteral nutrition supplements [ I dosages and routes not stated i ]. One of the two neonates developed cholestasis due to long-term parenteral nutrition supplements with hypoxic ischaemic encephalopathy; the other neonate concurrently developed intestinal dysmotility secondary to viral gastroenteritis [ I outcomes not stated i ]. [Extracted from the article]

In a single-centre, retrospective, observational study involving 20 paediatric patients, who received canakinumab between 1 November 2015 and 31 October 2017 through a vial-sharing programme, four patients [ I ages and sexes not stated i ] were described, who developed bacterial tracheitis, viral upper respiratory tract infection, varicella zoster virus infection or viral gastroenteritis following treatment with canakinumab for cryopyrin-associated periodic syndrome (CAPS). Subsequently, the patients developed bacterial tracheitis (n=1), presumed viral upper respiratory tract infection (n=1), uncomplicated varicella zoster virus infection (n=1) or presumed viral gastroenteritis [n=1; I durations of treatments to reactions onsets not stated i ]. "These were: bacterial tracheitis (n = 1); presumed viral upper respiratory tract infection (n = 1);... uncomplicated varicella zoster virus infection (n = 1); presumed viral gastroenteritis (n = 1).". [Extracted from the article]

An abstract of the article "Longterm beneficial effect of canakinumab in colchicine-resistant familial mediterranean fever," by K. Laskari and colleagues is presented.

The article describes two cases of urinary tract infection and viral gastroenteritis during treatment with canakinumab for Familial Mediterranean fever.